Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB14922 | Tislelizumab | An IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of unresectable, locally advanced or metastatic esophageal squamous cell carcinoma |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB09035 | Nivolumab | Programmed cell death protein 1 | target |
| DB09035 | Nivolumab | Programmed cell death 1 ligand 1 | target |
| DB14922 | Tislelizumab | Programmed cell death protein 1 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|